Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

NICE should speak up on rosiglitazone

I am very pleased with the new drug guidelines from NICE ('Gliptins given key diabetes role', pulsetoday.co.uk/news).

The institute is to be congratulated in devising an algorithm for health professionals in treatment of type 2 diabetes, with recommendations for both glitazones and gliptins second-line where there are concerns regarding hypoglycaemia.

It is a shame, however, that NICE was unable to give a clear lead on the continuing controversy of cardiovascular safety of rosiglitazone, which is tarnishing the image of the glitazones as a class.

From Professor Anthony Barnett, professor of medicine and honorary consultant physician at the University of Birmingham

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say